Amylyx Pharmaceuticals Files 8-K
Ticker: AMLX · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1658551
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Amylyx filed an 8-K on 9/10/25 for a material agreement. Details TBD.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The filing date for this report is September 9, 2025. No specific details of the agreement or financial figures were provided in the excerpt.
Why It Matters
This filing indicates a significant event or agreement for Amylyx Pharmaceuticals, potentially impacting its business operations or financial standing.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications presented.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of earliest event reported
- September 10, 2025 (date) — Date of Report
- 43 Thorndike St. (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
- 02141 (location) — Principal executive offices zip code
FAQ
What is the nature of the material definitive agreement entered into by Amylyx Pharmaceuticals?
The provided excerpt does not specify the details of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 9, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Amylyx Pharmaceuticals, Inc.
Where are Amylyx Pharmaceuticals' principal executive offices located?
Amylyx Pharmaceuticals' principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
What is the SEC file number for Amylyx Pharmaceuticals?
The SEC file number for Amylyx Pharmaceuticals is 001-41199.
Filing Stats: 1,181 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2025-09-10 16:55:03
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $10.00 — on Stock"), at a price to the public of $10.00 per share (the "Offering"). Pursuant to
- $164.0 m — e by the Company, will be approximately $164.0 million, or approximately $188.7 million
- $188.7 million — mately $164.0 million, or approximately $188.7 million if the option to purchase the Option Sh
Filing Documents
- d947193d8k.htm (8-K) — 31KB
- d947193dex11.htm (EX-1.1) — 184KB
- d947193dex51.htm (EX-5.1) — 7KB
- 0001193125-25-200159.txt ( ) — 384KB
- amlx-20250909.xsd (EX-101.SCH) — 3KB
- amlx-20250909_lab.xml (EX-101.LAB) — 17KB
- amlx-20250909_pre.xml (EX-101.PRE) — 11KB
- d947193d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated September 9, 2025 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: September 10, 2025 By: /s/ James M. Frates James M. Frates Chief Financial Officer